drugset / Trial / NCT00542555

Analgesic Efficacy and Safety Study of Naproxcinod in Subjects With Osteoarthritis of the Knee

NCT00542555

Phase 3 Completed 918 enrolled NicOx
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To study the efficacy and safety of naproxcinod vs. placebo and naproxen in the treatment of signs and symptoms of Osteoarthritis.

Timeline

Start
2005-12
Primary completion
Completion
2007-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Naproxen Small molecule 500 mg
Subject naproxcinod Other / unclassified 375 mg
Subject naproxcinod Other / unclassified 750 mg

Indications